Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 24 Sep 2026 · Editorial standards

Nivolumab is named as a drug or biological intervention in 96 clinical trials in our USA, UK, China, Ireland and India trial registers, 41 of which are recruiting. Lead sponsors include Bristol-Myers Squibb (24), Replimune, Inc. (5) and Exelixis (4). Registered phases: Phase 3, Phase 2, Phase 1/2, Phase 1, Phase 2/3, Observational, Phase 4 and Not applicable. Conditions studied include Melanoma; Solid Tumor; Gastric Cancer.

Nivolumab also has an approved-drug profile on this site (FDA label data): Opdivo (Nivolumab) →

Clinical trials of Nivolumab

96 trials

NCT ID	Study	Phase	Status	Lead sponsor	Register
NCT05317858	Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets Brain Tumor, Non Small Cell Lung Cancer	Phase 3	Recruiting	InSightec	USA
NCT06112314	IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301) (ClinicalTrials.gov ↗) Advanced Melanoma	Phase 3	Recruiting	Immunocore Ltd	UK, USA
NCT06246916	A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) (ClinicalTrials.gov ↗) Melanoma	Phase 3	Recruiting	Regeneron Pharmaceuticals	USA
NCT06264180	VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] (ClinicalTrials.gov ↗) Advanced Melanoma	Phase 3	Recruiting	Replimune, Inc.	UK, USA
NCT06561386	A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% Non-small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China
NCT06646276	A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). (ClinicalTrials.gov ↗) Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
NCT06743126	SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (ClinicalTrials.gov ↗) Melanoma, Cutaneous Malignant	Phase 3	Recruiting	Immatics US, Inc.	UK, USA
NCT07195695	Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China
NCT07405164	Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043) (ClinicalTrials.gov ↗) Von Hippel-Lindau Disease, Malignant Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA
NCT07431281	Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 (ClinicalTrials.gov ↗) Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT07541170	A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	USA
NCT07720284	An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC (ClinicalTrials.gov ↗) High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
NCT06581406	A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma (ClinicalTrials.gov ↗) Metastatic Uveal Melanoma	Phase 2/3	Recruiting	Replimune, Inc.	UK, USA
NCT07221149	A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) (ClinicalTrials.gov ↗) Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
NCT07392892	Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer (ClinicalTrials.gov ↗) Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma, Metastatic Gastric Cancer, Gastroesophageal Junction Cancer	Phase 2/3	Recruiting	Pfizer	USA, China
NCT03899155	Pan Tumor Rollover Study (ClinicalTrials.gov ↗) Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT05327686	Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial (ClinicalTrials.gov ↗) Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland
NCT05934331	A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (ClinicalTrials.gov ↗) Malignant Neoplasms of Digestive Organs	Phase 2	Recruiting	LaNova Medicines Zhejiang Co., Ltd.	China
NCT06554613	Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Phase 2	Recruiting	Second Affiliated Hospital of Nanchang University	China
NCT07219459	Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure (ClinicalTrials.gov ↗) Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound	Phase 2	Recruiting	CatalYm GmbH	UK, USA
NCT07246863	Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC (ClinicalTrials.gov ↗) Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA
NCT07398937	Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC (ClinicalTrials.gov ↗) Resectable Stage II-IIIa Squamous NSCLC	Phase 2	Recruiting	Fudan University	China
NCT07432295	Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) (ClinicalTrials.gov ↗) Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 2	Recruiting	I-Mab Biopharma US Limited	USA, China
NCT07492680	A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China
NCT07527858	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer Advanced Microsatellite Stable Colorectal Cancer	Phase 2	Recruiting	Gilead Sciences	USA
NCT07546812	Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma	Phase 2	Recruiting	Gilead Sciences	USA
NCT03686124	ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors (ClinicalTrials.gov ↗) Refractory Cancer, Recurrent Cancer, Solid Tumor, Adult	Phase 1/2	Recruiting	Immatics US, Inc.	USA
NCT04495296	A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Advanced Cancer	Phase 1/2	Recruiting	Transcenta Therapeutics (Hangzhou) Co., Ltd.	China
NCT05267626	Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer Advanced Solid Tumor, Metastatic Cancer, Cutaneous Melanoma	Phase 1/2	Recruiting	Aulos Bioscience, Inc.	USA
NCT05533697	Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Advanced Solid Tumors	Phase 1/2	Recruiting	ModernaTX, Inc.	UK, USA
NCT05584670	A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors Solid Tumor	Phase 1/2	Recruiting	Sanofi	USA
NCT05655312	MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma (ClinicalTrials.gov ↗) Recurrent Melanoma (Skin), Metastatic Melanoma, Melanoma Stage IV	Phase 1/2	Recruiting	Perspective Therapeutics	USA
NCT05919264	FOG-001 in Locally Advanced or Metastatic Solid Tumors (ClinicalTrials.gov ↗) Cancer, Colorectal Cancer, Solid Tumor	Phase 1/2	Recruiting	Parabilis Medicines, Inc.	USA
NCT06047379	Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (ClinicalTrials.gov ↗) Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc.	USA
NCT06362369	A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy (ClinicalTrials.gov ↗) Advanced Cancer, Advanced Solid Tumor, Melanoma	Phase 1/2	Recruiting	7 Hills Pharma, LLC	USA
NCT06618287	A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors Lung Cancer, Breast Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA
NCT07276373	Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies (ClinicalTrials.gov ↗) Neoplasms	Phase 1/2	Recruiting	Corcept Therapeutics	USA
NCT05076760	MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Advanced Cancer, Metastatic Cancer	Phase 1	Recruiting	Memgen, Inc.	USA
NCT05176483	Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors (ClinicalTrials.gov ↗) Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC)	Phase 1	Recruiting	Exelixis	UK, USA
NCT06399419	CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer (ClinicalTrials.gov ↗) Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma	Phase 1	Recruiting	Osel, Inc.	USA
NCT06764771	A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors (ClinicalTrials.gov ↗) Advanced Malignant Tumors	Phase 1	Recruiting	Bristol-Myers Squibb	USA
NCT07459543	A Study to Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Unresectable or Metastatic Melanoma Participants In India (ClinicalTrials.gov ↗) Unresectable Melanoma, Metastatic Melanoma	Phase 4	Not yet open	Bristol-Myers Squibb	India
NCT07700979	Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma (ClinicalTrials.gov ↗) Gastric / Gastroesophageal Junction Adenocarcinoma	Phase 3	Not yet open	Akeso	USA, China
NCT07403877	Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer (ClinicalTrials.gov ↗) Colorectal Cancer (MSI-H)	Phase 2	Not yet open	Fudan University	China
NCT07494435	Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC (ClinicalTrials.gov ↗) Hepato Cellular Carcinoma (HCC), Renal Cell Cancer	Phase 2	Not yet open	Zhejiang Haichang Biotech Co., Ltd.	China
NCT07620574	Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study (ClinicalTrials.gov ↗) Cancer, Renal Cell Carcinoma (RCC), Pancreatic Neuroendocrine Tumors (pNET)	Phase 3	By invitation	Exelixis	USA
NCT05745233	Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites (ClinicalTrials.gov ↗) Malignant Ascites	Not applicable	By invitation	China Medical University Hospital	China
NCT02785952	Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (ClinicalTrials.gov ↗) Recurrent Squamous Cell Lung Carcinoma, Stage IV Squamous Cell Lung Carcinoma AJCC v7	Phase 3	Active, closed	SWOG Cancer Research Network	Ireland
NCT03036098	Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer (ClinicalTrials.gov ↗) Urothelial Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	USA, China
NCT03383458	A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (ClinicalTrials.gov ↗) Hepatocellular Carcinoma, Liver Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA
NCT03522246	A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ClinicalTrials.gov ↗) Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer	Phase 3	Active, closed	pharmaand GmbH	Ireland, UK, USA, China
NCT03873402	A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer (ClinicalTrials.gov ↗) Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	USA
NCT03937219	Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA
NCT04008030	A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) Metastatic Colorectal Cancer	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT04025879	A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China
NCT04099251	Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (ClinicalTrials.gov ↗) Melanoma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA
NCT04674683	Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma (ClinicalTrials.gov ↗) Unresectable or Metastatic Melanoma, Progressive Brain Metastasis	Phase 3	Active, closed	HUYABIO International, LLC.	UK, USA
NCT04810078	A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (ClinicalTrials.gov ↗) Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, USA
NCT05144854	A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (ClinicalTrials.gov ↗) Gastric Cancer	Phase 3	Active, closed	Ono Pharmaceutical Co., Ltd.	China
NCT05625399	A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma (ClinicalTrials.gov ↗) Melanoma	Phase 3	Active, closed	Bristol-Myers Squibb	UK, USA
NCT05678673	Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma (ClinicalTrials.gov ↗) Non-Clear Cell Renal Cell Carcinoma	Phase 3	Active, closed	Exelixis	UK, USA
NCT06054555	A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma (ClinicalTrials.gov ↗) Melanoma	Phase 3	Active, closed	Amgen	USA, China
NCT06097728	MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (ClinicalTrials.gov ↗) Unresectable Pleural Mesothelioma	Phase 3	Active, closed	AstraZeneca	UK, USA, China
NCT03470922	A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (ClinicalTrials.gov ↗) Melanoma	Phase 2/3	Active, closed	Bristol-Myers Squibb	UK, USA
NCT05987332	IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma (ClinicalTrials.gov ↗) Metastatic Uveal Melanoma	Phase 2/3	Active, closed	IDEAYA Biosciences	UK, USA
NCT03228667	QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc.	USA
NCT03505320	A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
NCT03767348	Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC)	Phase 2	Active, closed	Replimune, Inc.	UK, USA
NCT03865082	Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) (ClinicalTrials.gov ↗) Solid Tumor	Phase 2	Active, closed	Idera Pharmaceuticals, Inc.	USA
NCT04015778	A Exploratory Study of Nivolumab Monotherapy or in Combination With Nab-paclitaxel and Carboplatin in Early Stage NSCLC in China Non Small Cell Lung Cancer	Phase 2	Active, closed	Guangdong Association of Clinical Trials	China
NCT05633667	Study of Novel Treatment Combinations in Patients With Lung Cancer (ClinicalTrials.gov ↗) Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
NCT06101134	A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations (ClinicalTrials.gov ↗) Melanoma	Phase 2	Active, closed	Bristol-Myers Squibb	USA
NCT06256328	A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer) (ClinicalTrials.gov ↗) Gastric Cancer	Phase 2	Active, closed	Ono Pharmaceutical Co., Ltd.	China
NCT06534983	A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab Alone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (MIUC) Muscle-invasive Urothelial Carcinoma	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA
NCT06946797	A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Phase 2	Active, closed	Bristol-Myers Squibb	USA
NCT03647163	Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma	Phase 1/2	Active, closed	Vyriad, Inc.	USA
NCT03907852	Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer (ClinicalTrials.gov ↗) Mesothelioma, Mesothelioma, Malignant, Mesothelioma; Pleura	Phase 1/2	Active, closed	TCR2 Therapeutics	USA
NCT04180371	Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (ClinicalTrials.gov ↗) Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA
NCT04396821	A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd.	USA
NCT05163041	Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA
NCT05180799	A Phase 1/2 Study of BA3071 in Patients With Solid Tumors (ClinicalTrials.gov ↗) NSCLC, Melanoma	Phase 1/2	Active, closed	BioAtla, Inc.	USA
NCT05888831	A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors	Phase 1/2	Active, closed	Bristol-Myers Squibb	USA
NCT02099058	A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors (ClinicalTrials.gov ↗) Advanced Solid Tumors Cancer	Phase 1	Active, closed	AbbVie	USA, China
NCT02293980	A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) (ClinicalTrials.gov ↗) ccRCC, RCC, Kidney Cancer	Phase 1	Active, closed	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)	USA
NCT02393625	Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (ClinicalTrials.gov ↗) ALK-positive NSCLC	Phase 1	Active, closed	Novartis Pharmaceuticals	USA
NCT02817633	A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (ClinicalTrials.gov ↗) Neoplasms	Phase 1	Active, closed	Tesaro, Inc.	USA
NCT03589339	NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy (ClinicalTrials.gov ↗) Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour	Phase 1	Active, closed	Nanobiotix	USA
NCT03872947	A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors (ClinicalTrials.gov ↗) Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
NCT04336241	Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors (ClinicalTrials.gov ↗) Cancer	Phase 1	Active, closed	Replimune, Inc.	UK
NCT04735978	Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours (ClinicalTrials.gov ↗) Advanced Solid Tumor	Phase 1	Active, closed	Replimune, Inc.	UK, USA
NCT04835805	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. (ClinicalTrials.gov ↗) Melanoma	Phase 1	Active, closed	Genentech, Inc.	USA
NCT05352828	Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy (ClinicalTrials.gov ↗) Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent	Phase 1	Active, closed	Tessa Therapeutics	USA
NCT06544655	A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors Advanced Solid Tumors	Phase 1	Active, closed	Bristol-Myers Squibb	USA
NCT07024862	Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy (ClinicalTrials.gov ↗) Metastatic Non-small Cell Lung Cancer	Observational	Active, closed	Bristol-Myers Squibb	USA
NCT07215962	Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1% (ClinicalTrials.gov ↗) Non-small Cell Lung Cancer (NSCLC)	Observational	Active, closed	Bristol-Myers Squibb	USA
NCT07718139	Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada (ClinicalTrials.gov ↗) Non-Small Cell Lung Cancer	Observational	Active, closed	Bristol-Myers Squibb	UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Conditions studied

131 conditions

Condition (as registered)	Trials
Melanoma	9
Solid Tumor	8
Gastric Cancer	6
Cancer	5
Non-Small Cell Lung Cancer	5
Advanced Cancer	5
Non-small Cell Lung Cancer	4
Advanced Solid Tumor	4
Non Small Cell Lung Cancer	4
Advanced Solid Tumors	3
Renal Cell Carcinoma (RCC)	3
Metastatic Cancer	3
Clear Cell Renal Cell Carcinoma	2
Renal Cell Carcinoma	2
Cutaneous Melanoma	2
Lung Cancer	2
Advanced Melanoma	2
Metastatic Uveal Melanoma	2
Urothelial Cancer	2
Esophageal Adenocarcinoma	2
Colorectal Cancer	2
Neoplasms	2
Metastatic Melanoma	2
Metastatic Colorectal Cancer	1
Carcinoma, Non-Small-Cell Lung	1
Solid Tumors	1
Recurrent Squamous Cell Lung Carcinoma	1
Stage IV Squamous Cell Lung Carcinoma AJCC v7	1
Epithelial Ovarian Cancer	1
Primary Peritoneal	1
Fallopian Tube Cancer	1
Newly Diagnosed	1
Metastatic Renal Cell Carcinoma	1
Stage III Renal Cell Cancer AJCC v8	1
Stage IV Renal Cell Cancer AJCC v8	1
Unresectable Renal Cell Carcinoma	1
Non-Small Cell Lung Cancer (NSCLC)	1
Microsatellite Instability-High (MSI-H)	1
Non-melanoma Skin Cancer (NMSC)	1
Breast Cancer	1

+ 91 more conditions in the trial records above.

Trials by country register

Register	Nivolumab trials
Clinical trials in USA	81
Clinical trials in UK	36
Clinical trials in China	28
Clinical trials in Ireland	9
Clinical trials in India	6

A trial with sites in more than one country appears in each of those registers.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Nivolumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Nivolumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Nivolumab

Clinical trials of Nivolumab

Conditions studied

Sponsors

Trials by country register

How this page is built